Sublingual grass and ragweed immunotherapy: Clinical considerations—a PRACTALL consensus report - 05/02/16
Doi : 10.1016/j.jaci.2015.06.046
James T. Li, MD, PhD a, ⁎ 
, David I. Bernstein, MD b, Moises A. Calderon, MD, PhD c, Thomas B. Casale, MD d, Linda Cox, MD e, Giovanni Passalacqua, MD f, Oliver Pfaar, MD g, h, Nikolaos G. Papadopoulos, MD i
, David I. Bernstein, MD b, Moises A. Calderon, MD, PhD c, Thomas B. Casale, MD d, Linda Cox, MD e, Giovanni Passalacqua, MD f, Oliver Pfaar, MD g, h, Nikolaos G. Papadopoulos, MD i a Division of Allergic Diseases, Mayo Clinic, Rochester, Minn
b University of Cincinnati, Cincinnati, Ohio
c Imperial College London, London, United Kingdom
d University of South Florida, Tampa, Fla
e Nova Southeastern University, Fort Lauderdale, Fla
f Allergy and Respiratory Diseases, University of Genoa, Genoa, Italy
g Center for Rhinology and Allergology, Wiesbaden, Germany
h Department of Otorhinolaryngology, Head and Neck Surgery, Universitatsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
i Allergy Research Center, Athens, Greece
∗Corresponding author: James T. Li, MD, PhD, Mayo Clinic, 200 First St, Rochester, MN 55905.
Abstract |
Sublingual allergen immunotherapy provides a new option for patients with allergic rhinitis in the United States. The efficacy of these sublingual immunotherapy tablets in the treatment of allergic rhinitis has been firmly established in large multicenter clinical trials. In addition, the clinical benefits of sublingual immunotherapy might persist after treatment is discontinued. Local reactions, such as gastrointestinal or oropharyngeal symptoms, are common. However, severe anaphylaxis is rare, and therefore the immunotherapy tablets can be administered at home. Sublingual immunotherapy for allergic rhinitis has been used successfully for years in Europe, and these products might be appropriate for patients who do not do well with standard drug therapy or for those who prefer a disease-modifying approach.
Le texte complet de cet article est disponible en PDF.Key words : Sublingual, immunotherapy, ragweed, sublingual immunotherapy
Abbreviations used : AIT, FDA, PI, SCIT, SLIT
Plan
| Disclosure of potential conflict of interest: D. I. Bernstein has received research support from Merck, Stallergenes, Greer, Amgen, Novartis, GlaxoSmithKline, Circassia, Johnson & Johnson, TEVA, Pfizer, Genentech, Boehringer Ingelheim, Astra Zeneca, and Novartis; has consultant arrangements with Merck, BVA, and Circassia; has received payment for service on the Scientific Advisory Committee for Merck; is a board member for the American Board of Allergy and Immunology and the Joint Task Force on Practice Parameters; and has received payment for lectures from Merck. M. A. Calderon has consultant agreements with ALK-Abelló (Germany/Denmark), HAL Allergy (The Netherlands/Germany), and Stallergenes (Germany/France). T. B. Casale has received grants from Stalleregenes and Merck and grants and personal fees from Circassia outside the submitted work and serves as Executive Vice President of the American Academy of Allergy, Asthma & Immunology. O. Pfaar has received research grants for his institution from ALK-Abelló (Germany/Denmark), Allergopharma (Germany), Stallergenes (Germany/France), HAL Allergy (Germany/The Netherlands), Artu Biologicals (The Netherlands), Allergy Therapeutics/Bencard (United Kingdom/Germany), Hartington (Spain), Lofarma (Italy), Novartis (Germany), LETI-Pharma/Laboratorios LETI (Germany/Spain), GlaxoSmithKline (United Kingdom/Germany), Essex Pharma (Germany), Cytos (Switzerland), Curalogic (Denmark), Roxall (Germany), Biomay (Austria), Thermo Fisher (Germany), Circassia (United Kingdom), European Union (FP-7 Health-2013 Innovation 1), Biotech Tools s.a. (Belgium), and MEDA Pharma (Germany); has served as an advisor and on speakers' bureaus for some of the aforementioned companies; has received travel grants from HAL Allergy (The Netherlands/Germany), Allergopharma (Germany), the European Academy of Allergy and Clinical Immunology (EAACI), the German Society for Allergology and Clinical Immunology (DGAKI), and the German Respiratory Society (DGP); is a consultant for Allergy Therapeutics/Bencard (United Kingdom/Germany), HAL Allergy (Germany/The Netherlands), Novartis (Germany), LETI Pharma/Laboratorios LETI (Germany/Spain), MEDA Pharma (Germany), ALK-Abelló (Germany/Denmark), Allergopharma (Germany), Biotech Tools s.a. (Belgium), GfK Bridgehead (UK), Navigant Consulting (United States), Sanofi (United States), Guidepoint Global Advisors (United States), Thermo Fisher (Germany), Pohl-Boskamp (Germany), Stallergenes (Germany/France), and Mobile Chamber Experts (MCX, a GA2LEN Partner); has been Coordinating Investigator in clinical trials of some of the aforementioned companies; is the current chairman of the Immunotherapy Interest Group (IT IG) of the EAACI and is the secretary of the ENT section of the DGAKI; has received grants for the “Spezifische Immuntherapie” award 2014 and the “Nachwuchsförderpreis” award 2010 of the DGAKI; is coeditor and author of different chapters of the textbook Allergien bei Kindern und Jugendlichen (publisher: Schattauer, Germany), author of one chapter in Allergologie (publisher: Springer, Germany), and author of different chapters in Allergologie (publisher: Schattauer, Germany); has received payment for development of educational presentations from GlaxoSmithKline (Germany), Bencard (Germany), ALK-Abelló (Germany/Denmark), Stallergenes (Germany/France), and Novartis (Germany); and is an editorial board member of Allergo Journal International. N. G. Papadopoulos has received research support from GlaxoSmithKline, Nestle, and Merck; has received payment for development of educational presentations from Abbvie, Sanofi, Menarini, and Meda; has received consultant fees from GlaxoSmithKline, Abbvie, Novartis, Menarini, Meda, and ALK-Abelló; and has received payment for lectures from Novartis, Allergopharma, Uriach, GlaxoSmithKline, Stallergenes, and MSD. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2015
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 137 - N° 2
P. 369-376 - février 2016 Retour au numéro
Article précédent
- International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics
- Marek Jutel, Ioana Agache, Sergio Bonini, A. Wesley Burks, Moises Calderon, Walter Canonica, Linda Cox, Pascal Demoly, Antony J. Frew, Robyn O'Hehir, Jörg Kleine-Tebbe, Antonella Muraro, Gideon Lack, Désirée Larenas, Michael Levin, Bryan L. Martin, Harald Nelson, Ruby Pawankar, Oliver Pfaar, Ronald van Ree, Hugh Sampson, James L. Sublett, Kazunari Sugita, George Du Toit, Thomas Werfel, Roy Gerth van Wijk, Luo Zhang, Mübeccel Akdis, Cezmi A. Akdis
- The Editors' Choice
- Cezmi A. Akdis, Zuhair K. Ballas, Associate Editors of the JACI
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?